FI924082A0 - Idiotypvaccination mot b-cellymfoma. - Google Patents

Idiotypvaccination mot b-cellymfoma.

Info

Publication number
FI924082A0
FI924082A0 FI924082A FI924082A FI924082A0 FI 924082 A0 FI924082 A0 FI 924082A0 FI 924082 A FI924082 A FI 924082A FI 924082 A FI924082 A FI 924082A FI 924082 A0 FI924082 A0 FI 924082A0
Authority
FI
Finland
Prior art keywords
dendritic cells
idiotype
pulsed
cells
idiotypvaccination
Prior art date
Application number
FI924082A
Other languages
English (en)
Other versions
FI105452B (fi
FI924082A (fi
Inventor
Heribert Bohlen
Jacques Urbain
Camp Benjamin Van
Kristiaan Thielemans
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23960532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI924082(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of FI924082A publication Critical patent/FI924082A/fi
Publication of FI924082A0 publication Critical patent/FI924082A0/fi
Application granted granted Critical
Publication of FI105452B publication Critical patent/FI105452B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
FI924082A 1990-03-14 1992-09-11 Idiotyyppirokotuksen valmistus B-solulymfoomaa vastaan FI105452B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/493,511 US20030072751A1 (en) 1990-03-14 1990-03-14 Idiotypic vaccination against b cell lymphoma
US49351190 1990-03-14
PCT/US1991/001683 WO1991013632A1 (en) 1990-03-14 1991-03-13 Idiotypic vaccination against b cell lymphoma
US9101683 1991-03-13

Publications (3)

Publication Number Publication Date
FI924082A FI924082A (fi) 1992-09-11
FI924082A0 true FI924082A0 (fi) 1992-09-11
FI105452B FI105452B (fi) 2000-08-31

Family

ID=23960532

Family Applications (1)

Application Number Title Priority Date Filing Date
FI924082A FI105452B (fi) 1990-03-14 1992-09-11 Idiotyyppirokotuksen valmistus B-solulymfoomaa vastaan

Country Status (12)

Country Link
US (1) US20030072751A1 (fi)
EP (1) EP0521897B1 (fi)
JP (1) JP2735947B2 (fi)
AT (1) ATE124265T1 (fi)
AU (1) AU645552B2 (fi)
CA (1) CA2078235C (fi)
DE (1) DE69110877T2 (fi)
DK (1) DK0521897T3 (fi)
ES (1) ES2074268T3 (fi)
FI (1) FI105452B (fi)
NO (1) NO308509B1 (fi)
WO (1) WO1991013632A1 (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) * 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
WO1993020185A1 (en) * 1992-04-01 1993-10-14 Steinman Ralph M Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DE69333433T2 (de) * 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
JPH07509251A (ja) * 1992-07-22 1995-10-12 ザ トラスティーズ オブ プリンストン ユニバーシティ ｐ５３ワクチン
WO1994004659A1 (en) * 1992-08-21 1994-03-03 United States Of America, As Represented By The Secretary, Department Of Health & Human Services A novel b-lymphoma cell line and antigen
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
EP0692973A1 (en) * 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
WO1995034638A1 (en) * 1994-06-14 1995-12-21 The Board Of Trustees Of Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
US6602709B1 (en) 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
EP1176986B1 (en) 1999-04-20 2018-07-04 Yale University Differentiation of monocytes into functional dendritic cells
US8313945B2 (en) 1999-04-20 2012-11-20 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AT409086B (de) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells

Also Published As

Publication number Publication date
AU645552B2 (en) 1994-01-20
FI105452B (fi) 2000-08-31
ATE124265T1 (de) 1995-07-15
CA2078235A1 (en) 1991-09-15
DE69110877D1 (de) 1995-08-03
CA2078235C (en) 2004-01-20
DK0521897T3 (da) 1995-11-13
JPH05507905A (ja) 1993-11-11
NO923542D0 (no) 1992-09-11
WO1991013632A1 (en) 1991-09-19
FI924082A (fi) 1992-09-11
NO923542L (no) 1992-09-11
DE69110877T2 (de) 1995-11-16
EP0521897B1 (en) 1995-06-28
ES2074268T3 (es) 1995-09-01
AU7488691A (en) 1991-10-10
JP2735947B2 (ja) 1998-04-02
EP0521897A1 (en) 1993-01-13
US20030072751A1 (en) 2003-04-17
NO308509B1 (no) 2000-09-25

Similar Documents

Publication Publication Date Title
FI924082A (fi) Idiotypvaccination mot b-cellymfoma
IT1248760B (it) Dispositivo di iniezione del combustibile per motori e endotermici
DK0504177T3 (da) IL-11, et pattedyrcytokin
DK0669836T3 (da) Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
DE3854174D1 (de) Kraftstoffeinspritzventil.
DE68924202T2 (de) Überschall-Kraftstoff-Einspritzdüse.
ES2124533T3 (es) Anticuerpos monoclonales inmunoestimulantes.
ZA846214B (en) Monoclonal antibodies with specificity for membrane-associated antigens
DE68922871T2 (de) Brennstoffeinspritzdüse.
MY135673A (en) Monoclonal antibodies for inducing tolerance
DE68912995T2 (de) Kraftstoffeinspritzventil.
IT8367392A0 (it) Polverizzatore per iniettori del combustibile di motori diesel
DE3886126D1 (de) Brennstoffeinspritzventil.
DE68917138T2 (de) Toleranzinduktion gegenüber einem fremdantigen.
IT1204628B (it) Inietori di combustibile
IT1203929B (it) Iniettore di combustibile per carburatore
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
DE69322960D1 (de) Empfängnisverhütender impfstoff
Thonard Host defense mechanisms in the oral mucosa
NO872633L (no) Monoklonalt antistoff mot humant plasminogen, samt fremstilling derav.
IT1229943B (it) Procedimento e dispositivo di misura dell'anticipo di inizio mandata dell'iniezione, particolarmente in motori diesel
IT8819312A0 (it) Iniettore di carburante.
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов
ITMI913291A0 (it) Dispositivo e procedimento di iniezione del combustibile

Legal Events

Date Code Title Description
MA Patent expired